Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/20/2022 | $6.00 → $3.00 | Buy | HC Wainwright & Co. |
| 9/30/2021 | $7.00 → $5.00 | Buy | Aegis Capital |
| 9/28/2021 | $6.00 | Buy | HC Wainwright & Co. |
4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
HC Wainwright & Co. reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $3.00 from $6.00 previously
Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $5.00 from $7.00 previously
HC Wainwright & Co. initiated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $6.00
SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger
SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.
SAN DIEGO, Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kint
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
EFFECT - Kintara Therapeutics, Inc. (0001498382) (Filer)
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, w
SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments. Recent Corporate Developments Announced that Kintara had entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Merge
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunitiesCompanies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ETSAN DIEGO and TAMPA, Fla., April 3, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a bi
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm
New York, March 03, 2021 (GLOBE NEWSWIRE) -- - Medexus Pharmaceuticals Inc (CVE:MDP) shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results click here - BioPorto A/S (CPH:BIOPOR) expects to complete its clinical study and submit a De Novo application to the US FDA for pediatric use of its NGAL kidney test this summer click here - EVmo Inc (OTCMKTS:YAYO) closes its controlling interest sale to Acuitas Group Holdings click here - Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) brings on Camargo Pharmaceutical Services to boost US FDA approval for Ivectsol click here - Alpine 4 Technologies Ltd (OTCQB:ALPP) appoi
SAN DIEGO, March 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Mario Lacouture, M.D. to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer (CMBC). "We are pleased to welcome Dr. Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debilitating oncology indication," commented Saiid Zarrabian, Kintara's Chief Executive Officer. "We look forward to working closely with Dr. La
SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)
SC 13G - Kintara Therapeutics, Inc. (0001498382) (Subject)
SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)